SYNBIOTIC SE Faces Regulatory Challenges but Retains Growth Prospects

SYNBIOTIC SE, a European holding company in the medical cannabis and industrial hemp sectors, is adjusting to new regulatory challenges. With twelve holdings, SYNBIOTIC's structure supports synergy across the cultivation, processing, product development, and distribution stages. Recent organizational restructuring aims to strengthen its control over value-adding processes.

The company faces headwinds due to proposed regulations that might ban online sales of medical cannabis and limit digital prescriptions, impacting demand. Consequently, SYNBIOTIC revised its 2025 sales forecast down to €17 million and predicts an EBITDA loss of €1.5 million.

Despite these setbacks, the company continues to focus on innovation, exemplified by the upcoming release of a cannabis pastille. This new product is anticipated to hit the market in early 2026, potentially enhancing SYNBIOTIC’s medical portfolio. Additionally, legislative changes in industrial hemp are expected, promising future growth opportunities.